How to Get Evenity (Romosozumab) in Mississippi

What Is Romosozumab and Why Does It Matter for Mississippi Patients?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab both stimulates new bone growth and reduces bone resorption, a dual mechanism unique among osteoporosis therapies [1]. The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk of fracture [2].

Mississippi has one of the highest osteoporosis burden rates in the southeastern United States. According to CDC data, approximately 10.3% of adults aged 50 and older in Mississippi have osteoporosis, compared with the national average of 12.6% [3]. The state's rural geography and limited specialist access make telehealth and pharmacy logistics especially relevant for patients who need a monthly injectable like romosozumab. The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months (6.2% vs. 11.9%, P<0.001) [4]. That trial established romosozumab as the most potent bone-building agent currently available, but the drug carries a boxed warning: it may increase cardiovascular risk, including myocardial infarction and stroke.

For Mississippi patients, accessing this therapy involves coordinating prescribers, insurance coverage, and specialty pharmacy logistics. Each step has state-specific considerations.

How to Get a Romosozumab Prescription in Mississippi

The first step is a confirmed diagnosis of osteoporosis with high fracture risk. Most insurers and the FDA label require a DEXA scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip [2]. Your prescriber will also evaluate your 10-year fracture probability using the FRAX calculator, with most plans requiring a major osteoporotic fracture probability exceeding 20% or a hip fracture probability exceeding 3% [5].

Mississippi allows MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe romosozumab. NPs in Mississippi have full practice authority after completing a supervised collaboration period, meaning they can independently prescribe Schedule II through V controlled substances and non-controlled specialty medications like romosozumab [6]. PAs must maintain a collaborative agreement with a supervising physician but can prescribe within that scope.

Your prescriber will need to document:

• DEXA T-score results (dated within 24 months)
• Fracture history, especially vertebral or hip fractures
• Failure of or intolerance to a prior osteoporosis therapy (often required for prior authorization)
• Cardiovascular risk assessment, since the boxed warning contraindicates use in patients who have had a myocardial infarction or stroke within the preceding year [2]

Dr. Felicia Cosman, a senior clinical director at the National Osteoporosis Foundation, has stated: "Romosozumab should be considered first-line for patients at very high fracture risk, particularly those with recent fractures, because the anabolic window is limited to 12 months and delays reduce benefit" [7].

Telehealth Access for Evenity in Mississippi

Mississippi permits telehealth prescribing for romosozumab. Yes, this is legal. The Mississippi State Board of Medical Licensure recognizes telehealth encounters as valid for establishing and maintaining prescriber-patient relationships, including for specialty medications [8].

A telehealth visit for romosozumab typically involves a video consultation where the prescriber reviews your DEXA scan, fracture history, and cardiovascular risk factors. You will still need in-person labs and a DEXA scan completed at a local imaging center before the telehealth appointment. The prescriber cannot order the initial DEXA remotely in all cases, but can interpret results and initiate treatment during a virtual visit.

Telehealth is particularly valuable in Mississippi's rural counties. The Mississippi State Department of Health reports that 54 of the state's 82 counties are classified as medically underserved [9]. For patients in the Delta region or southern pine belt, driving two or more hours to see an endocrinologist or rheumatologist is common. A telehealth prescriber can initiate the romosozumab prescription and coordinate with a local infusion center or home health nurse for the monthly injections.

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines note: "Telehealth delivery of osteoporosis management, including initiation of anabolic agents, is appropriate when baseline imaging and laboratory data are available for review" [10].

Insurance Coverage and Prior Authorization in Mississippi

Mississippi Medicaid does not cover Evenity for severe osteoporosis as of 2026. This is a significant barrier for the estimated 22% of Mississippi adults enrolled in Medicaid [11]. Patients on Medicaid who need romosozumab must pursue manufacturer assistance programs or appeal through the state's exceptions process.

Commercial insurance plans in Mississippi, including Blue Cross Blue Shield of Mississippi (the state's dominant carrier), typically cover Evenity but require prior authorization. The standard prior authorization criteria include:

• Documented osteoporosis (T-score ≤ -2.5)
• History of fragility fracture or very high FRAX score
• Trial and failure of at least one antiresorptive agent (alendronate, risedronate, or denosumab)
• No history of myocardial infarction or stroke within the past 12 months
• Prescriber attestation that the patient will transition to an antiresorptive agent after completing the 12-month romosozumab course

The prior authorization process in Mississippi typically takes 5 to 14 business days. If denied, the prescriber can submit a peer-to-peer review. Amgen's Evenity Access Solutions program provides copay assistance for commercially insured patients, reducing out-of-pocket costs to as low as $5 per injection for eligible patients [12].

Medicare Part B covers Evenity as a physician-administered injectable under the medical benefit, not the pharmacy benefit. This distinction matters. Medicare patients receive Evenity in a clinical setting (physician office, infusion center, or hospital outpatient department), and the drug is billed under J-code J3111 [13]. The 2026 Medicare average sales price for romosozumab is approximately $1,825 per monthly injection, and patients are responsible for the 20% coinsurance after meeting their Part B deductible.

Required Labs Before Starting Evenity in Mississippi

Before the first injection, your prescriber must order baseline laboratory tests. These are not optional. The Evenity prescribing information and AACE guidelines specify the following labs [2][10]:

Calcium and vitamin D levels. Hypocalcemia must be corrected before initiating romosozumab. The prescribing information states that serum calcium should be within normal range prior to each dose. Patients with 25-hydroxyvitamin D levels below 30 ng/mL should receive supplementation for at least 4 to 8 weeks before starting treatment.

Renal function. A basic metabolic panel including serum creatinine and estimated GFR helps assess calcium handling and guides vitamin D dosing. Romosozumab has not been studied in patients with severe renal impairment (eGFR <30 mL/min), so prescribers exercise caution in this population.

Bone turnover markers. While not strictly required, many specialists order baseline serum CTX (C-terminal telopeptide) and P1NP (procollagen type 1 N-terminal propeptide) to monitor treatment response. A study published in the Journal of Bone and Mineral Research found that P1NP increased by 145% within one month of romosozumab initiation, confirming the rapid anabolic effect [14].

Cardiovascular screening. Given the boxed warning, most Mississippi prescribers will obtain a baseline lipid panel, blood pressure measurement, and cardiac history review. Patients with a 10-year ASCVD risk score exceeding 20% require a risk-benefit discussion before starting therapy.

These labs can be completed at any clinical laboratory in Mississippi. LabCorp and Quest Diagnostics both have draw sites across the state, including in Jackson, Gulfport, Hattiesburg, Tupelo, and Meridian.

Pharmacy and Dispensing Options in Mississippi

Evenity is a specialty medication that requires cold-chain storage (2°C to 8°C) and comes as two prefilled syringes per monthly dose. Each 210 mg dose is administered as two separate 105 mg injections, given one immediately after the other at different injection sites [2].

Mississippi has several specialty pharmacy options for obtaining romosozumab:

Hospital outpatient pharmacies. The University of Mississippi Medical Center (UMMC) in Jackson operates a specialty pharmacy that stocks Evenity for its osteoporosis clinic patients. Baptist Memorial Health Care and Memorial Hospital at Gulfport also maintain outpatient infusion services where the drug can be administered.

National specialty pharmacies. Optum Specialty Pharmacy, CVS Specialty, and Accredo (Express Scripts) ship Evenity to Mississippi addresses with cold-chain packaging. Delivery typically arrives within 3 to 5 business days after prior authorization approval.

503A compounding pharmacies. Mississippi licenses 503A compounding pharmacies that can prepare patient-specific prescriptions. However, romosozumab is a biologic monoclonal antibody that cannot be compounded from raw ingredients under current 503A regulations. The 503A designation applies to dispensing and handling, not to manufacturing biosimilar versions of the drug. Patients should be aware that no compounded alternative to Evenity exists. The 503A pharmacies in Mississippi can receive, store, and dispense the commercially manufactured product.

Buy-and-bill model. Many prescribers in Mississippi use the buy-and-bill model, where the physician's office purchases Evenity directly from a distributor, administers the injections on-site, and bills the patient's insurance. This model is standard for Medicare Part B patients and avoids the need for a separate specialty pharmacy.

Timeline from Consultation to First Injection

Patients often ask how long the process takes. Here is a realistic timeline for Mississippi residents:

Week 1. Schedule a consultation (in-person or telehealth). If DEXA and labs are already completed, the prescriber can submit a prior authorization during this visit.

Week 2 to 3. If labs and DEXA are needed first, expect one to two weeks for scheduling and results. Mississippi imaging centers typically schedule DEXA scans within 5 to 10 business days.

Week 3 to 5. Prior authorization review. Commercial plans average 5 to 14 business days. Medicare Part B claims are typically processed faster, within 3 to 7 business days.

Week 4 to 6. Drug delivery or office stocking. Once authorization is approved, specialty pharmacy shipping takes 3 to 5 business days. Buy-and-bill offices may already have stock.

Week 5 to 7. First injection. Total elapsed time from initial consultation to first dose ranges from 3 to 7 weeks for most Mississippi patients.

The FRAME trial (N=7,180) demonstrated that romosozumab produced a 73% reduction in new vertebral fractures compared with placebo at 12 months (0.5% vs. 1.8%, P<0.001) [15]. Starting treatment promptly after a fracture is important because the refracture risk is highest in the first 12 to 24 months.

Transitioning After the 12-Month Romosozumab Course

Romosozumab is approved for only 12 monthly doses. This is not a lifelong therapy. After the 12-dose course, the anabolic bone-building effect diminishes, and bone density gains can reverse without follow-up treatment [2].

The ARCH trial protocol transitioned patients from romosozumab to alendronate 70 mg weekly, and this sequence maintained the bone density gains achieved during the anabolic phase [4]. The Endocrine Society's 2019 clinical practice guideline recommends transitioning to a bisphosphonate (alendronate, risedronate, or zoledronic acid) or denosumab after completing romosozumab [16].

Your Mississippi prescriber should discuss the transition plan before initiating romosozumab. Denosumab (Prolia) is one option, administered as a 60 mg subcutaneous injection every 6 months. Zoledronic acid (Reclast) is another, given as a single annual IV infusion. Both are available through the same specialty pharmacy and infusion center channels in Mississippi.

Do not stop romosozumab without starting a follow-up antiresorptive. A study in the Journal of Bone and Mineral Research showed that patients who discontinued romosozumab without transitioning to an antiresorptive lost 85% of the gained bone mineral density at the lumbar spine within 12 months [14].

Cardiovascular Safety Considerations

The FDA added a boxed warning to Evenity's label based on the ARCH trial data, which showed a higher rate of adjudicated major adverse cardiovascular events (MACE) in the romosozumab group compared with alendronate during the first 12 months: 2.5% vs. 1.9% [4]. The absolute risk difference was 0.6 percentage points.

This warning means that prescribers in Mississippi must screen patients for cardiovascular disease before writing the prescription. Romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the previous 12 months [2]. For patients with cardiovascular risk factors but no recent events, the prescriber must weigh the fracture risk reduction against the potential cardiovascular signal.

The American College of Rheumatology's 2022 osteoporosis treatment guideline conditionally recommends romosozumab for very high-risk patients even with moderate cardiovascular risk, stating that "the fracture risk reduction benefit may outweigh the uncertain cardiovascular signal in appropriately selected patients" [17].